首页 > 最新文献

JAC-Antimicrobial Resistance最新文献

英文 中文
Antifungal stewardship in the UK: where are we now? 英国的抗真菌管理:我们现在在哪里?
IF 3.7 Q2 INFECTIOUS DISEASES Pub Date : 2024-12-31 eCollection Date: 2025-02-01 DOI: 10.1093/jacamr/dlae209
Silke Schelenz, Samir Agrawal, Aaron Brady, Gillian Kiely, Zeshan Riaz, Emilie Howes, Tim Felton, Christianne Micallef, Netta Tyler, Tihana Bicanic, P Lewis White

Background: Antifungal stewardship (AFS) is the judicious use of today's antifungal agents with the aim of improving patient outcomes and preserving their future effectiveness. Antifungal resistance (AFR) is increasing globally, with more patients at risk of Invasive Fungal Disease (IFD), highlighting the urgent need to standardize AFS practices in the UK. The aim of this position paper is to understand the current AFS landscape in the UK.

Methods: A virtual panel discussion was held from September to October 2023 on an online platform followed by a virtual meeting with nine healthcare professionals from across the UK selected for their expertise on IFD management and AFS. The discussion was structured across four topics: current AFS landscape, key elements of an AFS programme, diagnostics and diagnostic stewardship, and unmet needs in education and training. A thematic analysis was carried out. The results represent the collated and summarized views from these activities.

Results and discussion: Participants reported barriers to implementing AFS and its integration within antimicrobial stewardship (AMS) programmes in the UK. The primary challenge identified was a lack of resources, including funding and staff time. Sub-optimal fungal diagnostics and limited mycology expertise was reported as a barrier to AFS, clinical IFD and AFR surveillance. Approaches to combatting these challenges may include investing in formal mycology networks to serve as centres of clinical expertise and diagnostic hubs.

Conclusion: National standards for AFS services and associated outcome metrics need to be established to set a benchmark for centres to improve AFS.

背景:抗真菌管理(AFS)是明智地使用当今的抗真菌药物,目的是改善患者的预后并保持其未来的有效性。抗真菌耐药性(AFR)在全球范围内不断增加,越来越多的患者面临侵袭性真菌疾病(IFD)的风险,这凸显了英国对AFS实践标准化的迫切需要。本立场文件的目的是了解当前AFS在英国的格局。方法:于2023年9月至10月在在线平台上举行虚拟小组讨论,随后与来自英国各地的9名医疗保健专业人员进行虚拟会议,这些专业人员在IFD管理和AFS方面获得了专业知识。讨论围绕四个主题展开:AFS的现状、AFS计划的关键要素、诊断和诊断管理,以及教育和培训方面未满足的需求。进行了专题分析。结果是对这些活动的观点进行整理和总结的结果。结果和讨论:与会者报告了在英国实施AFS及其与抗菌药物管理(AMS)计划整合的障碍。确定的主要挑战是缺乏资源,包括资金和工作人员时间。据报道,不理想的真菌诊断和有限的真菌学专业知识是AFS,临床IFD和AFR监测的障碍。应对这些挑战的方法可能包括投资于正式的真菌学网络,作为临床专业知识中心和诊断中心。结论:需要建立AFS服务和相关结果指标的国家标准,为中心改善AFS设置基准。
{"title":"Antifungal stewardship in the UK: where are we now?","authors":"Silke Schelenz, Samir Agrawal, Aaron Brady, Gillian Kiely, Zeshan Riaz, Emilie Howes, Tim Felton, Christianne Micallef, Netta Tyler, Tihana Bicanic, P Lewis White","doi":"10.1093/jacamr/dlae209","DOIUrl":"10.1093/jacamr/dlae209","url":null,"abstract":"<p><strong>Background: </strong>Antifungal stewardship (AFS) is the judicious use of today's antifungal agents with the aim of improving patient outcomes and preserving their future effectiveness. Antifungal resistance (AFR) is increasing globally, with more patients at risk of Invasive Fungal Disease (IFD), highlighting the urgent need to standardize AFS practices in the UK. The aim of this position paper is to understand the current AFS landscape in the UK.</p><p><strong>Methods: </strong>A virtual panel discussion was held from September to October 2023 on an online platform followed by a virtual meeting with nine healthcare professionals from across the UK selected for their expertise on IFD management and AFS. The discussion was structured across four topics: current AFS landscape, key elements of an AFS programme, diagnostics and diagnostic stewardship, and unmet needs in education and training. A thematic analysis was carried out. The results represent the collated and summarized views from these activities.</p><p><strong>Results and discussion: </strong>Participants reported barriers to implementing AFS and its integration within antimicrobial stewardship (AMS) programmes in the UK. The primary challenge identified was a lack of resources, including funding and staff time. Sub-optimal fungal diagnostics and limited mycology expertise was reported as a barrier to AFS, clinical IFD and AFR surveillance. Approaches to combatting these challenges may include investing in formal mycology networks to serve as centres of clinical expertise and diagnostic hubs.</p><p><strong>Conclusion: </strong>National standards for AFS services and associated outcome metrics need to be established to set a benchmark for centres to improve AFS.</p>","PeriodicalId":14594,"journal":{"name":"JAC-Antimicrobial Resistance","volume":"7 1","pages":"dlae209"},"PeriodicalIF":3.7,"publicationDate":"2024-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11685713/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142914744","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Molecular characterization of antibiotic resistance in bacteria from daycare centres in Ile-Ife, Nigeria. 尼日利亚Ile-Ife日托中心细菌抗生素耐药性的分子特征
IF 3.7 Q2 INFECTIOUS DISEASES Pub Date : 2024-12-30 eCollection Date: 2025-02-01 DOI: 10.1093/jacamr/dlae213
Eunice Damilola Wilkie, Jude Oluwapelumi Alao, Oluwakemi Abike Thonda, Anthonia Olufunke Oluduro

Background: Antibiotic resistance is an escalating global health issue, with particularly severe implications in low- and middle-income countries (LMICs) such as Nigeria. This study examines antibiotic-resistant bacteria's prevalence and molecular characteristics in daycare centres in Ile-Ife, Nigeria, where high antibiotic use and limited infection control measures present significant challenges.

Methods: Between November 2017 and July 2019, samples were collected from 20 daycare centres, including swabs from fomites and children. Bacterial isolates were identified and assessed for antibiotic susceptibility using standard methods. Molecular techniques, including PCR, were employed to detect resistance genes such as blaSHV, tetA, dfr1 and mecA.

Results: The study found high resistance levels among common pathogens, with S. aureus and other staphylococci showing significant resistance to ampicillin and Augmentin and Gram-negative bacteria exhibiting broad resistance patterns. Resistance genes, including blaSHV and mecA, were identified in multiple isolates, indicating the spread of crucial resistance mechanisms.

Conclusions: The results highlight the critical need for improved surveillance, targeted antimicrobial stewardship and enhanced infection control practices in daycare centres to address the growing threat of antibiotic resistance. This research offers valuable insights into resistance dynamics in paediatric settings and supports the development of strategies to manage the spread of resistant bacteria in LMIC contexts.

背景:抗生素耐药性是一个不断升级的全球健康问题,对尼日利亚等中低收入国家的影响尤为严重。本研究探讨了抗生素耐药性细菌在尼日利亚伊费岛日托中心的流行情况和分子特征:方法:2017 年 11 月至 2019 年 7 月期间,从 20 个日托中心采集了样本,包括从粪便和儿童身上采集的拭子。采用标准方法对细菌分离物进行鉴定和抗生素敏感性评估。采用包括 PCR 在内的分子技术检测耐药基因,如 blaSHV、tetA、dfr1 和 mecA:结果:研究发现,常见病原体的耐药性水平很高,金黄色葡萄球菌和其他葡萄球菌对氨苄西林和奥门汀有明显的耐药性,而革兰氏阴性菌则表现出广泛的耐药性模式。在多个分离菌株中发现了耐药基因,包括 blaSHV 和 mecA,这表明重要的耐药机制正在扩散:研究结果突出表明,日托中心亟需加强监测、有针对性地开展抗菌药物管理和强化感染控制措施,以应对日益严重的抗生素耐药性威胁。这项研究为了解儿科环境中的耐药性动态提供了有价值的见解,并有助于制定策略来控制耐药细菌在低收入和中等收入国家的传播。
{"title":"Molecular characterization of antibiotic resistance in bacteria from daycare centres in Ile-Ife, Nigeria.","authors":"Eunice Damilola Wilkie, Jude Oluwapelumi Alao, Oluwakemi Abike Thonda, Anthonia Olufunke Oluduro","doi":"10.1093/jacamr/dlae213","DOIUrl":"10.1093/jacamr/dlae213","url":null,"abstract":"<p><strong>Background: </strong>Antibiotic resistance is an escalating global health issue, with particularly severe implications in low- and middle-income countries (LMICs) such as Nigeria. This study examines antibiotic-resistant bacteria's prevalence and molecular characteristics in daycare centres in Ile-Ife, Nigeria, where high antibiotic use and limited infection control measures present significant challenges.</p><p><strong>Methods: </strong>Between November 2017 and July 2019, samples were collected from 20 daycare centres, including swabs from fomites and children. Bacterial isolates were identified and assessed for antibiotic susceptibility using standard methods. Molecular techniques, including PCR, were employed to detect resistance genes such as <i>blaSHV</i>, <i>tetA</i>, <i>dfr1</i> and <i>mecA</i>.</p><p><strong>Results: </strong>The study found high resistance levels among common pathogens, with <i>S. aureus</i> and other staphylococci showing significant resistance to ampicillin and Augmentin and Gram-negative bacteria exhibiting broad resistance patterns. Resistance genes, including <i>blaSHV</i> and <i>mecA</i>, were identified in multiple isolates, indicating the spread of crucial resistance mechanisms.</p><p><strong>Conclusions: </strong>The results highlight the critical need for improved surveillance, targeted antimicrobial stewardship and enhanced infection control practices in daycare centres to address the growing threat of antibiotic resistance. This research offers valuable insights into resistance dynamics in paediatric settings and supports the development of strategies to manage the spread of resistant bacteria in LMIC contexts.</p>","PeriodicalId":14594,"journal":{"name":"JAC-Antimicrobial Resistance","volume":"7 1","pages":"dlae213"},"PeriodicalIF":3.7,"publicationDate":"2024-12-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11683008/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142907183","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Doctors' perceptions of antimicrobial resistance in the Northern West Bank, Palestine: a qualitative study. 医生对巴勒斯坦西岸北部抗菌素耐药性的看法:一项定性研究。
IF 3.7 Q2 INFECTIOUS DISEASES Pub Date : 2024-12-26 eCollection Date: 2025-02-01 DOI: 10.1093/jacamr/dlae198
Lotta Gustafsson, Zaher Nazzal, Connie Mary Wiskin, Souad Belkebir, Shameq Sayeed, Alix Wood

Objectives: In the West Bank, antimicrobial resistance (AMR) is increasingly and alarmingly common. Efforts are being made to introduce antimicrobial stewardship programmes (ASPs). This study explores doctors' perceptions of AMR and context-specific barriers and facilitators to ASPs at a critical point in national ASP development.

Methods: Semi-structured interviews were conducted with 22 doctors working in primary healthcare, government and non-governmental hospitals in Nablus in 2019. Two researchers thematically analysed the data.

Results: Participants recognized antibiotic resistance as a major threat to health. Few felt that doctors were well informed about ASPs; many had not heard of them. However, there was willingness to expand and begin new education programmes. Barriers and facilitators to ASPs included: (i) doctors were perceived to 'misuse' antibiotics, lack awareness, favour short-term outcomes, and externalize blame; (ii) patients reportedly treat antibiotics 'like analgesia' with high expectations of doctors; (iii) resource limitations make ASPs and infection control difficult-a lack of drugs, laboratory services, infectious disease specialists, and research to develop local guidelines; and (iv) top-down policy is recommended to restrict access to antibiotics without a prescription, but should be coupled with support, collaboration and community action.

Conclusions: Doctors' appreciation of the severity of the issue, and willingness for the expansion of existing programmes targeted at their own prescribing practices, provides a strong foundation for successful ASPs. A top-down approach to prevent inappropriate antibiotic prescribing is welcomed by participating doctors. If financial and resource limitations could be addressed, a continued multifaceted approach may enable physician, pharmacist and patient behaviours to change.

目的:在西岸,抗菌素耐药性(AMR)日益普遍,令人震惊。正在努力引入抗微生物药物管理规划(asp)。本研究探讨了在国家ASP发展的关键时刻,医生对抗菌素耐药性的看法以及特定情境下的ASP障碍和促进因素。方法:对2019年在纳布卢斯初级卫生保健、政府和非政府医院工作的22名医生进行半结构化访谈。两位研究人员对这些数据进行了主题分析。结果:参与者认识到抗生素耐药性是对健康的主要威胁。很少有人认为医生对asp有充分的了解;很多人都没听说过。但是,有扩大和开始新的教育方案的意愿。asp的障碍和促进因素包括:(i)医生被认为“滥用”抗生素,缺乏认识,偏爱短期结果,并将责任外部化;(ii)据报道,患者把抗生素当作“镇痛药”对待,对医生抱有很高的期望;(iii)资源有限,使得asp和感染控制变得困难——缺乏药物、实验室服务、传染病专家和制定当地指南的研究;(iv)建议采取自上而下的政策限制无处方抗生素的获取,但应辅以支持、合作和社区行动。结论:医生认识到问题的严重性,并愿意针对自己的处方实践扩大现有方案,为成功的asp提供了坚实的基础。参与的医生欢迎自上而下的方法来防止不当的抗生素处方。如果财政和资源限制可以解决,一个持续的多方面的方法可能使医生,药剂师和病人的行为改变。
{"title":"Doctors' perceptions of antimicrobial resistance in the Northern West Bank, Palestine: a qualitative study.","authors":"Lotta Gustafsson, Zaher Nazzal, Connie Mary Wiskin, Souad Belkebir, Shameq Sayeed, Alix Wood","doi":"10.1093/jacamr/dlae198","DOIUrl":"10.1093/jacamr/dlae198","url":null,"abstract":"<p><strong>Objectives: </strong>In the West Bank, antimicrobial resistance (AMR) is increasingly and alarmingly common. Efforts are being made to introduce antimicrobial stewardship programmes (ASPs). This study explores doctors' perceptions of AMR and context-specific barriers and facilitators to ASPs at a critical point in national ASP development.</p><p><strong>Methods: </strong>Semi-structured interviews were conducted with 22 doctors working in primary healthcare, government and non-governmental hospitals in Nablus in 2019. Two researchers thematically analysed the data.</p><p><strong>Results: </strong>Participants recognized antibiotic resistance as a major threat to health. Few felt that doctors were well informed about ASPs; many had not heard of them. However, there was willingness to expand and begin new education programmes. Barriers and facilitators to ASPs included: (i) doctors were perceived to 'misuse' antibiotics, lack awareness, favour short-term outcomes, and externalize blame; (ii) patients reportedly treat antibiotics 'like analgesia' with high expectations of doctors; (iii) resource limitations make ASPs and infection control difficult-a lack of drugs, laboratory services, infectious disease specialists, and research to develop local guidelines; and (iv) top-down policy is recommended to restrict access to antibiotics without a prescription, but should be coupled with support, collaboration and community action.</p><p><strong>Conclusions: </strong>Doctors' appreciation of the severity of the issue, and willingness for the expansion of existing programmes targeted at their own prescribing practices, provides a strong foundation for successful ASPs. A top-down approach to prevent inappropriate antibiotic prescribing is welcomed by participating doctors. If financial and resource limitations could be addressed, a continued multifaceted approach may enable physician, pharmacist and patient behaviours to change.</p>","PeriodicalId":14594,"journal":{"name":"JAC-Antimicrobial Resistance","volume":"7 1","pages":"dlae198"},"PeriodicalIF":3.7,"publicationDate":"2024-12-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11670781/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142903281","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Bacterial growth and antimicrobial resistance in urinary Escherichia coli isolates among men with lower UTI in Swedish primary healthcare: retrospective data over a 4 year period. 瑞典初级保健中尿路感染较低的男性尿中大肠杆菌分离株的细菌生长和抗菌素耐药性:4年的回顾性数据
IF 3.7 Q2 INFECTIOUS DISEASES Pub Date : 2024-12-26 eCollection Date: 2025-02-01 DOI: 10.1093/jacamr/dlae214
Helena Kornfält Isberg, Martin Sundqvist, Eva Melander, Anders Beckman, Katarina Hedin

Background: Escherichia coli, the most common bacterium causing urinary tract infections (UTIs), is increasingly reported as resistant to multiple antibiotics. Swedish surveillance data from hospital and primary health care (PHC) report a 17%-19% prevalence of resistance to ciprofloxacin in E. coli from urine cultures in men over 20 years of age. Surveillance data may include nosocomial infections. However, few studies have described resistance in E. coli in men with community-acquired UTI in PHC. We aimed to describe the microbiological results, including antibiotic resistance in E. coli, in men with lower UTI (LUTI) attending PHC.

Methods: In this retrospective study based on information from electronic medical records, we included patients from 289 PHC centres. For all men aged 18-79 years diagnosed with LUTI in PHC from January 2012 to December 2015, we extracted data on age, UTI diagnosis and results from urine cultures.

Results: A total of 17 987 episodes of lower UTI were identified. E. coli was detected in 62% of positive cultures and 63% of detected E. coli isolates were susceptible to all tested antimicrobials. Resistance in E. coli to the first-choice antibiotics pivmecillinam and nitrofurantoin were 2% and 1%, respectively. Resistance to ciprofloxacin was 9%, and to trimethoprim it was 17%.

Conclusions: Resistance levels for ciprofloxacin in E. coli among men with LUTI in PHC were lower than in surveillance data. The results of this study point to the importance of surveillance of resistance in urine samples from patients with LUTI in PHC in order to choose the right empirical antibiotic treatment.

背景:大肠杆菌是引起尿路感染(uti)的最常见细菌,对多种抗生素具有耐药性的报道越来越多。瑞典医院和初级卫生保健(PHC)的监测数据显示,20岁以上男性尿液培养的大肠杆菌对环丙沙星的耐药性为17%-19%。监测数据可能包括医院感染。然而,很少有研究描述了PHC社区获得性尿路感染男性中大肠杆菌的耐药性。我们的目的是描述微生物结果,包括大肠杆菌的抗生素耐药性,在低尿路感染(LUTI)的男性参加PHC。方法:在这项基于电子病历信息的回顾性研究中,我们纳入了来自289个初级保健中心的患者。对于2012年1月至2015年12月在PHC诊断为尿路感染的所有年龄在18-79岁的男性,我们提取了年龄、尿路感染诊断和尿培养结果的数据。结果:共发现17 987例下尿路感染。在62%的阳性培养物中检测到大肠杆菌,63%的检测到的大肠杆菌分离物对所有测试的抗菌素敏感。大肠杆菌对首选抗生素哌美西林和呋喃妥英的耐药率分别为2%和1%。对环丙沙星的耐药率为9%,对甲氧苄啶的耐药率为17%。结论:PHC男性LUTI患者大肠杆菌对环丙沙星的耐药水平低于监测数据。本研究结果表明,监测尿路感染患者尿液样本的耐药性对于选择正确的经验性抗生素治疗具有重要意义。
{"title":"Bacterial growth and antimicrobial resistance in urinary <i>Escherichia coli</i> isolates among men with lower UTI in Swedish primary healthcare: retrospective data over a 4 year period.","authors":"Helena Kornfält Isberg, Martin Sundqvist, Eva Melander, Anders Beckman, Katarina Hedin","doi":"10.1093/jacamr/dlae214","DOIUrl":"10.1093/jacamr/dlae214","url":null,"abstract":"<p><strong>Background: </strong><i>Escherichia coli</i>, the most common bacterium causing urinary tract infections (UTIs), is increasingly reported as resistant to multiple antibiotics. Swedish surveillance data from hospital and primary health care (PHC) report a 17%-19% prevalence of resistance to ciprofloxacin in <i>E. coli</i> from urine cultures in men over 20 years of age. Surveillance data may include nosocomial infections. However, few studies have described resistance in <i>E. coli</i> in men with community-acquired UTI in PHC. We aimed to describe the microbiological results, including antibiotic resistance in <i>E. coli</i>, in men with lower UTI (LUTI) attending PHC.</p><p><strong>Methods: </strong>In this retrospective study based on information from electronic medical records, we included patients from 289 PHC centres. For all men aged 18-79 years diagnosed with LUTI in PHC from January 2012 to December 2015, we extracted data on age, UTI diagnosis and results from urine cultures.</p><p><strong>Results: </strong>A total of 17 987 episodes of lower UTI were identified. <i>E. coli</i> was detected in 62% of positive cultures and 63% of detected <i>E. coli</i> isolates were susceptible to all tested antimicrobials. Resistance in <i>E. coli</i> to the first-choice antibiotics pivmecillinam and nitrofurantoin were 2% and 1%, respectively. Resistance to ciprofloxacin was 9%, and to trimethoprim it was 17%.</p><p><strong>Conclusions: </strong>Resistance levels for ciprofloxacin in <i>E. coli</i> among men with LUTI in PHC were lower than in surveillance data. The results of this study point to the importance of surveillance of resistance in urine samples from patients with LUTI in PHC in order to choose the right empirical antibiotic treatment.</p>","PeriodicalId":14594,"journal":{"name":"JAC-Antimicrobial Resistance","volume":"7 1","pages":"dlae214"},"PeriodicalIF":3.7,"publicationDate":"2024-12-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11670775/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142903280","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Mentorship advances antimicrobial use surveillance systems in low- and middle-income countries. 导师制促进了低收入和中等收入国家的抗微生物药物使用监测系统。
IF 3.7 Q2 INFECTIOUS DISEASES Pub Date : 2024-12-26 eCollection Date: 2025-02-01 DOI: 10.1093/jacamr/dlae212
Kiran Sunder Bajracharya, Susan Luu, Ron Cheah, Santosh Kc, Atifa Mushtaq, Marjorie Elijah, Bhupendra Kumar Poudel, Celeste Fernandes Xavier Cham, Shyamu Mandal, Stephen Muhi, Kirsty Buising

A shortage of trained personnel poses significant challenges to implementing antimicrobial use (AMU) surveillance systems in low- and middle-income countries (LMICs). Traditional training models, such as workshops, seminars and online courses, often lack the sustained engagement and support necessary for deep learning and skill mastery. This article advocates for mentorship as an effective training method for AMU professionals in LMICs. Drawing on our experiences as mentors and mentees from 1- to 2-year mentorship programmes in Nepal, Pakistan, Papua New Guinea and Timor-Leste between 2019 and 2023, we highlight the challenges and success factors of mentorship. Our insights demonstrate mentorship's value in building expertise and sustaining capacity in AMU surveillance, offering a promising solution to address the personnel shortage in these regions.

缺乏训练有素的人员对在低收入和中等收入国家实施抗菌素使用监测系统构成重大挑战。传统的培训模式,如讲习班、研讨会和在线课程,往往缺乏深度学习和技能掌握所需的持续参与和支持。本文主张将师徒关系作为中低收入国家的AMU专业人员的有效培训方法。根据我们在2019年至2023年期间在尼泊尔、巴基斯坦、巴布亚新几内亚和东帝汶开展的1至2年师徒计划中作为导师和学员的经验,我们强调了师徒计划的挑战和成功因素。我们的见解证明了导师在建立专业知识和维持AMU监控能力方面的价值,为解决这些地区的人员短缺问题提供了一个有希望的解决方案。
{"title":"Mentorship advances antimicrobial use surveillance systems in low- and middle-income countries.","authors":"Kiran Sunder Bajracharya, Susan Luu, Ron Cheah, Santosh Kc, Atifa Mushtaq, Marjorie Elijah, Bhupendra Kumar Poudel, Celeste Fernandes Xavier Cham, Shyamu Mandal, Stephen Muhi, Kirsty Buising","doi":"10.1093/jacamr/dlae212","DOIUrl":"10.1093/jacamr/dlae212","url":null,"abstract":"<p><p>A shortage of trained personnel poses significant challenges to implementing antimicrobial use (AMU) surveillance systems in low- and middle-income countries (LMICs). Traditional training models, such as workshops, seminars and online courses, often lack the sustained engagement and support necessary for deep learning and skill mastery. This article advocates for mentorship as an effective training method for AMU professionals in LMICs. Drawing on our experiences as mentors and mentees from 1- to 2-year mentorship programmes in Nepal, Pakistan, Papua New Guinea and Timor-Leste between 2019 and 2023, we highlight the challenges and success factors of mentorship. Our insights demonstrate mentorship's value in building expertise and sustaining capacity in AMU surveillance, offering a promising solution to address the personnel shortage in these regions.</p>","PeriodicalId":14594,"journal":{"name":"JAC-Antimicrobial Resistance","volume":"7 1","pages":"dlae212"},"PeriodicalIF":3.7,"publicationDate":"2024-12-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11670778/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142903282","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pharmacokinetic/pharmacodynamic analysis of sulbactam against Acinetobacter baumannii pneumonia: establishing in vivo efficacy targets in the epithelial lining fluid. 舒巴坦抗鲍曼不动杆菌肺炎的药代动力学/药效学分析:在上皮内膜液中建立体内疗效靶点。
IF 3.7 Q2 INFECTIOUS DISEASES Pub Date : 2024-12-20 eCollection Date: 2024-12-01 DOI: 10.1093/jacamr/dlae203
Yasmeen Abouelhassan, Joseph L Kuti, David P Nicolau, Kamilia Abdelraouf

Background: Sulbactam is an effective therapy for Acinetobacter baumannii infections. Previous sulbactam pharmacokinetics/pharmacodynamics (PK/PD) analyses established exposure efficacy targets in plasma against A. baumannii pneumonia. Herein, we established sulbactam efficacy targets in epithelial lining fluid (ELF). The PTA following clinical sulbactam regimens was estimated.

Methods: Sulbactam (dosed as ampicillin-sulbactam) bronchopulmonary PK was assessed in the neutropenic murine pneumonia model. The percentage of the dosing interval during which the free drug concentration remained above the MIC (%fT > MIC) required to achieve different efficacy endpoints was estimated in 21 clinical A. baumannii isolates. PTA was assessed using Monte Carlo Simulations and utilizing previously published healthy volunteers sulbactam ELF pharmacokinetics.

Results: Median (IQR) %fT > MIC required to achieve 1-log kill in isolates resistant to both sulbactam and meropenem was 47.51 (39.7-54.2). This target was much higher than isolates with other phenotypes (i.e. sulbactam-susceptible/intermediate and sulbactam-resistant but meropenem susceptible) that required 16.62 (5.3-22.0). The PTA following sulbactam 1 g q6h 0.5h infusion regimen was >90% up to MIC of 2 mg/L while the PTA for MIC 4 mg/L (susceptibility breakpoint) was 81%. Conversely, previous assessment in plasma demonstrated the same regimen exceeded 90% PTA up to MIC of 4 mg/L. Sulbactam 3 g q8h 4h infusion provided PTA >90% for MIC 8 mg/L (sulbactam-intermediate), similar to previous assessment in plasma.

Conclusion: Based on the ELF assessment, the maximum FDA approved dose of sulbactam (1 g q6h 0.5h infusion) provided >90% PTA for isolates with sulbactam MIC only up to 2 mg/L. Nevertheless, sulbactam 3 g q8h for 4 hours of infusion achieved higher PTA and conferred additional benefit against sulbactam-susceptible/intermediate isolates.

背景:舒巴坦是治疗鲍曼不动杆菌感染的有效药物。先前的舒巴坦药代动力学/药效学(PK/PD)分析确定了血浆暴露对鲍曼不动杆菌肺炎的疗效靶点。在此,我们建立了舒巴坦在上皮衬里液(ELF)中的药效靶点。估计临床舒巴坦方案后的PTA。方法:舒巴坦(氨苄西林-舒巴坦)在嗜中性粒细胞减少小鼠肺炎模型中进行支气管肺PK测定。在21个临床鲍曼不动杆菌分离株中,估计游离药物浓度保持在达到不同疗效终点所需的MIC (%fT > MIC)以上的给药间隔时间的百分比。利用蒙特卡罗模拟和先前发表的健康志愿者舒巴坦ELF药代动力学来评估PTA。结果:对舒巴坦和美罗培南均耐药的分离株实现1-log杀伤所需的中位数(IQR) %fT > MIC为47.51(39.7-54.2)。这一目标远高于其他表型(即舒巴坦敏感/中间型和舒巴坦耐药但美罗培南敏感)的分离株,后者需要16.62(5.3-22.0)。舒巴坦1 g q6h 0.5h输注至MIC为2 mg/L时,PTA为90%,MIC为4 mg/L时(药敏断点)PTA为81%。相反,先前的血浆评估显示,相同方案的PTA超过90%,直至MIC为4 mg/L。舒巴坦3 g q8h输注4h,对于MIC 8 mg/L(舒巴坦中间体),PTA可达90%以上,与先前在血浆中的评估相似。结论:基于ELF评估,FDA批准的舒巴坦最大剂量(1 g q6h 0.5h输注)对舒巴坦MIC仅为2 mg/L的分离株的PTA可达90%。然而,舒巴坦3 g q8h输注4小时获得更高的PTA,并赋予舒巴坦敏感/中间分离株额外的益处。
{"title":"Pharmacokinetic/pharmacodynamic analysis of sulbactam against <i>Acinetobacter baumannii</i> pneumonia: establishing <i>in vivo</i> efficacy targets in the epithelial lining fluid.","authors":"Yasmeen Abouelhassan, Joseph L Kuti, David P Nicolau, Kamilia Abdelraouf","doi":"10.1093/jacamr/dlae203","DOIUrl":"10.1093/jacamr/dlae203","url":null,"abstract":"<p><strong>Background: </strong>Sulbactam is an effective therapy for <i>Acinetobacter baumannii</i> infections. Previous sulbactam pharmacokinetics/pharmacodynamics (PK/PD) analyses established exposure efficacy targets in plasma against <i>A. baumannii</i> pneumonia. Herein, we established sulbactam efficacy targets in epithelial lining fluid (ELF). The PTA following clinical sulbactam regimens was estimated.</p><p><strong>Methods: </strong>Sulbactam (dosed as ampicillin-sulbactam) bronchopulmonary PK was assessed in the neutropenic murine pneumonia model. The percentage of the dosing interval during which the free drug concentration remained above the MIC (%<i>f</i>T > MIC) required to achieve different efficacy endpoints was estimated in 21 clinical <i>A. baumannii</i> isolates. PTA was assessed using Monte Carlo Simulations and utilizing previously published healthy volunteers sulbactam ELF pharmacokinetics.</p><p><strong>Results: </strong>Median (IQR) %<i>f</i>T > MIC required to achieve 1-log kill in isolates resistant to both sulbactam and meropenem was 47.51 (39.7-54.2). This target was much higher than isolates with other phenotypes (i.e. sulbactam-susceptible/intermediate and sulbactam-resistant but meropenem susceptible) that required 16.62 (5.3-22.0). The PTA following sulbactam 1 g q6h 0.5h infusion regimen was >90% up to MIC of 2 mg/L while the PTA for MIC 4 mg/L (susceptibility breakpoint) was 81%. Conversely, previous assessment in plasma demonstrated the same regimen exceeded 90% PTA up to MIC of 4 mg/L. Sulbactam 3 g q8h 4h infusion provided PTA >90% for MIC 8 mg/L (sulbactam-intermediate), similar to previous assessment in plasma.</p><p><strong>Conclusion: </strong>Based on the ELF assessment, the maximum FDA approved dose of sulbactam (1 g q6h 0.5h infusion) provided >90% PTA for isolates with sulbactam MIC only up to 2 mg/L. Nevertheless, sulbactam 3 g q8h for 4 hours of infusion achieved higher PTA and conferred additional benefit against sulbactam-susceptible/intermediate isolates.</p>","PeriodicalId":14594,"journal":{"name":"JAC-Antimicrobial Resistance","volume":"6 6","pages":"dlae203"},"PeriodicalIF":3.7,"publicationDate":"2024-12-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11660682/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142876506","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Antimicrobial resistance-attributable mortality: a patient-level analysis. 抗菌素耐药性导致的死亡率:一项患者水平的分析。
IF 3.7 Q2 INFECTIOUS DISEASES Pub Date : 2024-12-19 eCollection Date: 2024-12-01 DOI: 10.1093/jacamr/dlae202
Ioannis Baltas, Timothy Miles Rawson, Hamish Houston, Louis Grandjean, Gabriele Pollara

Background: The impact of antimicrobial resistance (AMR) on death at the patient level is challenging to estimate. We aimed to characterize AMR-attributable deaths in a large UK teaching hospital.

Methods: This retrospective study investigated all deceased patients in 2022. Records of participants were independently reviewed by two investigators for cases of AMR-attributable deaths using a newly proposed patient-level definition.

Results: In total, 758 patients met inclusion criteria. Infection was the underlying cause of death for 11.7% (89/758) and was implicated in the pathway that led to death in 41.1% (357/758) of participants. In total, 4.2% (32/758) of all deaths were AMR-attributable. Median time from index sample collection to death was 4.5 days (IQR 2-10.5 days). The majority of AMR-attributable deaths (56.3%, 18/32) were associated with intrinsic resistance mechanisms, primarily by Enterococcus faecium (20.7%), Enterobacterales carrying repressed chromosomal ampicillinase Cs (AmpCs) (14.7%) and Pseudomonas aeruginosa (11.8%), whereas a minority (43.7%, 14/32) had acquired resistance mechanisms, primarily derepressed chromosomal AmpCs (11.8%) and ESBLs (8.8%). The median time to effective treatment was 32 h 15 min (no difference between subgroups). Only 62.5% (20/32) of AMR-attributable deaths had infection recorded on the death certificate. AMR was not recorded as a cause of death in any of the patients.

Conclusions: Infection and AMR were important causes of death in our cohort, yet they were significantly underreported during death certification. In a low-incidence setting for AMR, pathogen-antimicrobial mismatch due to intrinsic resistance was an equally important contributor to AMR-attributable mortality as acquired resistance mechanisms.

背景:抗微生物药物耐药性(AMR)对患者死亡的影响很难估计。我们的目的是在英国一家大型教学医院描述抗菌素耐药性导致的死亡。方法:对2022年所有死亡患者进行回顾性研究。两名调查人员使用新提出的患者级别定义独立审查了参与者的记录,以确定抗菌素耐药性导致的死亡病例。结果:758例患者符合纳入标准。感染是11.7%(89/758)的潜在死亡原因,并与导致41.1%(357/758)参与者死亡的途径有关。总的来说,4.2%(32/758)的死亡是抗菌素耐药性所致。从指标样本采集到死亡的中位时间为4.5天(IQR 2-10.5天)。大多数amr导致的死亡(56.3%,18/32)与内在耐药机制有关,主要是粪肠球菌(20.7%),携带抑制染色体氨苄青霉素酶Cs (AmpCs)(14.7%)和铜绿假单胞菌(11.8%),而少数(43.7%,14/32)具有获得性耐药机制,主要是染色体AmpCs(11.8%)和ESBLs(8.8%)。有效治疗的中位时间为32 h 15 min(亚组间无差异)。只有62.5%(20/32)的抗菌素耐药性导致的死亡在死亡证明上有感染记录。AMR未被记录为任何患者的死亡原因。结论:在我们的队列中,感染和AMR是重要的死亡原因,但在死亡证明中它们明显被低估了。在抗菌素耐药性低发病率的环境中,由于内在耐药导致的病原体-抗菌素错配与获得性耐药机制一样,都是导致抗菌素耐药性死亡率的重要因素。
{"title":"Antimicrobial resistance-attributable mortality: a patient-level analysis.","authors":"Ioannis Baltas, Timothy Miles Rawson, Hamish Houston, Louis Grandjean, Gabriele Pollara","doi":"10.1093/jacamr/dlae202","DOIUrl":"10.1093/jacamr/dlae202","url":null,"abstract":"<p><strong>Background: </strong>The impact of antimicrobial resistance (AMR) on death at the patient level is challenging to estimate. We aimed to characterize AMR-attributable deaths in a large UK teaching hospital.</p><p><strong>Methods: </strong>This retrospective study investigated all deceased patients in 2022. Records of participants were independently reviewed by two investigators for cases of AMR-attributable deaths using a newly proposed patient-level definition.</p><p><strong>Results: </strong>In total, 758 patients met inclusion criteria. Infection was the underlying cause of death for 11.7% (89/758) and was implicated in the pathway that led to death in 41.1% (357/758) of participants. In total, 4.2% (32/758) of all deaths were AMR-attributable. Median time from index sample collection to death was 4.5 days (IQR 2-10.5 days). The majority of AMR-attributable deaths (56.3%, 18/32) were associated with intrinsic resistance mechanisms, primarily by <i>Enterococcus faecium</i> (20.7%), Enterobacterales carrying repressed chromosomal ampicillinase Cs (AmpCs) (14.7%) and <i>Pseudomonas aeruginosa</i> (11.8%<i>)</i>, whereas a minority (43.7%, 14/32) had acquired resistance mechanisms, primarily derepressed chromosomal AmpCs (11.8%) and ESBLs (8.8%). The median time to effective treatment was 32 h 15 min (no difference between subgroups). Only 62.5% (20/32) of AMR-attributable deaths had infection recorded on the death certificate. AMR was not recorded as a cause of death in any of the patients.</p><p><strong>Conclusions: </strong>Infection and AMR were important causes of death in our cohort, yet they were significantly underreported during death certification. In a low-incidence setting for AMR, pathogen-antimicrobial mismatch due to intrinsic resistance was an equally important contributor to AMR-attributable mortality as acquired resistance mechanisms.</p>","PeriodicalId":14594,"journal":{"name":"JAC-Antimicrobial Resistance","volume":"6 6","pages":"dlae202"},"PeriodicalIF":3.7,"publicationDate":"2024-12-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11656165/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142864185","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Leveraging local public health to advance antimicrobial stewardship (AMS) implementation and mitigate antimicrobial resistance (AMR): a scoping review. 利用地方公共卫生促进抗菌素管理(AMS)的实施和减轻抗菌素耐药性(AMR):范围审查。
IF 3.7 Q2 INFECTIOUS DISEASES Pub Date : 2024-12-18 eCollection Date: 2024-12-01 DOI: 10.1093/jacamr/dlae187
Valerie Leung, Diane Ashiru-Oredope, Lauri Hicks, Sarah Kabbani, Mehdi Aloosh, Irene E Armstrong, Kevin A Brown, Nick Daneman, Kevin Lam, Hamidah Meghani, Mahad Nur, Kevin L Schwartz, Bradley J Langford

Objective: To explore the role of local public health organisations in antimicrobial stewardship (AMS) and antimicrobial resistance (AMR) surveillance.

Methods: A scoping review was conducted. Peer-reviewed and grey literature from countries within the organisation for economic co-operation and development was searched between 1999 and 2023 using the concepts of local public health, AMR and AMS. Thematic analysis was performed to identify themes.

Results: There were 63 citations illustrating 122 examples of AMS and AMR surveillance activities with local public health involvement. Common AMS activities (n = 105) included healthcare worker education (n = 22), antimicrobial use (AMU) evaluation (n = 21), patient/public education (n = 17), clinical practice guidelines (n = 10), and antibiograms (n = 10). Seventeen citations described local public health activities in AMR surveillance; the majority focussed on communicable diseases (n = 11) and/or AMR organisms (n = 6).

Conclusions: Local public health capabilities should be leveraged to advance high-impact activities to mitigate AMR, particularly in the areas of knowledge translation/mobilisation, optimising surveillance and establishing strategic collaborations.

Policy implications: Future work should focus on better understanding barriers and facilitators, including funding, to local public health participation in these activities.

目的:探讨地方公共卫生机构在抗菌药物管理(AMS)和耐药性(AMR)监测中的作用。方法:进行范围综述。在1999年至2023年期间,利用当地公共卫生、抗菌素耐药性和辅助医学的概念检索了经济合作与发展组织内各国的同行评议文献和灰色文献。进行主题分析以确定主题。结果:共发现63篇文献,122例地方公共卫生参与的AMS和AMR监测活动。常见的AMS活动(n = 105)包括医护人员教育(n = 22)、抗菌素使用(AMU)评估(n = 21)、患者/公众教育(n = 17)、临床实践指南(n = 10)和抗生素图(n = 10)。17条引文描述了当地在抗菌素耐药性监测方面的公共卫生活动;大多数集中于传染病(n = 11)和/或抗菌素耐药性生物(n = 6)。结论:应利用地方公共卫生能力推进高影响力活动,以减轻抗菌素耐药性,特别是在知识转化/动员、优化监测和建立战略合作等领域。政策影响:今后的工作应侧重于更好地了解当地公共卫生部门参与这些活动的障碍和促进因素,包括资金。
{"title":"Leveraging local public health to advance antimicrobial stewardship (AMS) implementation and mitigate antimicrobial resistance (AMR): a scoping review.","authors":"Valerie Leung, Diane Ashiru-Oredope, Lauri Hicks, Sarah Kabbani, Mehdi Aloosh, Irene E Armstrong, Kevin A Brown, Nick Daneman, Kevin Lam, Hamidah Meghani, Mahad Nur, Kevin L Schwartz, Bradley J Langford","doi":"10.1093/jacamr/dlae187","DOIUrl":"10.1093/jacamr/dlae187","url":null,"abstract":"<p><strong>Objective: </strong>To explore the role of local public health organisations in antimicrobial stewardship (AMS) and antimicrobial resistance (AMR) surveillance.</p><p><strong>Methods: </strong>A scoping review was conducted. Peer-reviewed and grey literature from countries within the organisation for economic co-operation and development was searched between 1999 and 2023 using the concepts of local public health, AMR and AMS. Thematic analysis was performed to identify themes.</p><p><strong>Results: </strong>There were 63 citations illustrating 122 examples of AMS and AMR surveillance activities with local public health involvement. Common AMS activities (<i>n</i> = 105) included healthcare worker education (<i>n</i> = 22), antimicrobial use (AMU) evaluation (<i>n</i> = 21), patient/public education (<i>n</i> = 17), clinical practice guidelines (<i>n</i> = 10), and antibiograms (<i>n</i> = 10). Seventeen citations described local public health activities in AMR surveillance; the majority focussed on communicable diseases (<i>n</i> = 11) and/or AMR organisms (<i>n</i> = 6).</p><p><strong>Conclusions: </strong>Local public health capabilities should be leveraged to advance high-impact activities to mitigate AMR, particularly in the areas of knowledge translation/mobilisation, optimising surveillance and establishing strategic collaborations.</p><p><strong>Policy implications: </strong>Future work should focus on better understanding barriers and facilitators, including funding, to local public health participation in these activities.</p>","PeriodicalId":14594,"journal":{"name":"JAC-Antimicrobial Resistance","volume":"6 6","pages":"dlae187"},"PeriodicalIF":3.7,"publicationDate":"2024-12-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11651725/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142854200","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
'Some patients demand for a prescription of an antibiotic': an assessment of barriers and facilitators to rational antimicrobial use in a private health facility in Uganda. “一些病人要求开抗生素处方”:对乌干达一家私营卫生机构合理使用抗微生物药物的障碍和促进因素的评估。
IF 3.7 Q2 INFECTIOUS DISEASES Pub Date : 2024-12-18 eCollection Date: 2024-12-01 DOI: 10.1093/jacamr/dlae204
Mark Kizito, Rejani Lalitha, Henry Kajumbula, Richard Muhumuza, Moses Grace Kintu, David Muyanja, Pauline Byakika-Kibwika

Background: Antimicrobial misuse and overuse propagate antimicrobial resistance, yet data on factors influencing antibiotic prescription decisions in low-resource settings are limited. We describe factors influencing antimicrobial prescription at a large tertiary care private not-for-profit hospital in Uganda.

Methods: We conducted a descriptive phenomenology qualitative study involving face-to-face in-depth interviews of 12 purposively selected prescribers (four intern doctors, six medical officers and two Internal Medicine physicians) in a private not-for-profit hospital in Kampala, Uganda. Audio recordings and filed notes were transcribed verbatim and analysed manually by content analysis. Emerging themes and sub-themes were recorded and reported.

Results: Three broad themes emerged: experience with antimicrobial use in Uganda, barriers and facilitators to rational antimicrobial prescription and measures to address irrational antimicrobial use. Participants recognized that antibiotics are often used irrationally, prescribed even when there is uncertainty regarding clinical evidence for infection, and influenced by drug promoters, and noted high levels of antibiotic resistance. Patients' symptoms and clinical signs, previous experience using antibiotics, fear of bad outcomes, patient demand and expectations, influence from senior colleagues, the turnaround time of clinical investigations and drug marketers were the barriers and facilitators to antimicrobial prescription. Prescribers also acknowledged the need to update clinical guidelines, set up hospital antibiograms, and provide continuous medical education on rational antimicrobial use.

Conclusions: A complex interplay of intrinsic and extrinsic factors influences antibiotic prescribing decisions in this hospital. Targeted interventions through continuous education and training for prescribers, providing local prescription guidelines and antibiograms and implementing regulations on over-the-counter antibiotic sales are needed to implement robust antimicrobial stewardship programmes to curb antimicrobial resistance successfully.

背景:抗菌素滥用和过度使用传播抗菌素耐药性,但在低资源环境下影响抗生素处方决策因素的数据有限。我们描述了影响抗菌药物处方的因素在乌干达一家大型三级护理私人非营利性医院。方法:我们对乌干达坎帕拉一家私人非营利性医院的12名处方者(4名实习医生、6名医务官员和2名内科医生)进行了描述现象学定性研究,其中包括面对面深入访谈。录音和存档笔记逐字抄录,并通过内容分析手工分析。记录和报告了新出现的主题和分主题。结果:出现了三个广泛的主题:乌干达抗菌素使用的经验,合理抗菌素处方的障碍和促进因素以及解决不合理抗菌素使用的措施。与会者认识到,抗生素的使用往往不合理,即使在感染的临床证据不确定的情况下也会开处方,并受到药物促进剂的影响,并注意到抗生素耐药性很高。患者的症状和临床体征、以往使用抗生素的经验、对不良结果的恐惧、患者的需求和期望、资深同事的影响、临床调查的周转时间和药品营销人员是抗菌药物处方的障碍和促进因素。开处方者也承认有必要更新临床指南,建立医院抗生素图,并提供关于合理使用抗微生物药物的持续医学教育。结论:影响该院抗生素处方决策的内在因素和外在因素的复杂相互作用。需要通过对开处方者的持续教育和培训、提供当地处方指南和抗生素图以及实施非处方抗生素销售条例等有针对性的干预措施,才能实施强有力的抗菌素管理规划,成功遏制抗菌素耐药性。
{"title":"'Some patients demand for a prescription of an antibiotic': an assessment of barriers and facilitators to rational antimicrobial use in a private health facility in Uganda.","authors":"Mark Kizito, Rejani Lalitha, Henry Kajumbula, Richard Muhumuza, Moses Grace Kintu, David Muyanja, Pauline Byakika-Kibwika","doi":"10.1093/jacamr/dlae204","DOIUrl":"10.1093/jacamr/dlae204","url":null,"abstract":"<p><strong>Background: </strong>Antimicrobial misuse and overuse propagate antimicrobial resistance, yet data on factors influencing antibiotic prescription decisions in low-resource settings are limited. We describe factors influencing antimicrobial prescription at a large tertiary care private not-for-profit hospital in Uganda.</p><p><strong>Methods: </strong>We conducted a descriptive phenomenology qualitative study involving face-to-face in-depth interviews of 12 purposively selected prescribers (four intern doctors, six medical officers and two Internal Medicine physicians) in a private not-for-profit hospital in Kampala, Uganda. Audio recordings and filed notes were transcribed verbatim and analysed manually by content analysis. Emerging themes and sub-themes were recorded and reported.</p><p><strong>Results: </strong>Three broad themes emerged: experience with antimicrobial use in Uganda, barriers and facilitators to rational antimicrobial prescription and measures to address irrational antimicrobial use. Participants recognized that antibiotics are often used irrationally, prescribed even when there is uncertainty regarding clinical evidence for infection, and influenced by drug promoters, and noted high levels of antibiotic resistance. Patients' symptoms and clinical signs, previous experience using antibiotics, fear of bad outcomes, patient demand and expectations, influence from senior colleagues, the turnaround time of clinical investigations and drug marketers were the barriers and facilitators to antimicrobial prescription. Prescribers also acknowledged the need to update clinical guidelines, set up hospital antibiograms, and provide continuous medical education on rational antimicrobial use.</p><p><strong>Conclusions: </strong>A complex interplay of intrinsic and extrinsic factors influences antibiotic prescribing decisions in this hospital. Targeted interventions through continuous education and training for prescribers, providing local prescription guidelines and antibiograms and implementing regulations on over-the-counter antibiotic sales are needed to implement robust antimicrobial stewardship programmes to curb antimicrobial resistance successfully.</p>","PeriodicalId":14594,"journal":{"name":"JAC-Antimicrobial Resistance","volume":"6 6","pages":"dlae204"},"PeriodicalIF":3.7,"publicationDate":"2024-12-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11652716/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142854201","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Behavioural impact of antibiotic stewardship in children in primary care: interviews with GPs and parents. 初级保健中抗生素管理对儿童行为的影响:与全科医生和家长的访谈。
IF 3.7 Q2 INFECTIOUS DISEASES Pub Date : 2024-12-17 eCollection Date: 2024-12-01 DOI: 10.1093/jacamr/dlae207
Erinn D'hulster, Marina Digregorio, Tine De Burghgraeve, Jeroen Luyten, Samuel Coenen, Sibyl Anthierens, Jan Y Verbakel

Background: The ARON study, a randomized controlled trial, assesses a behavioural intervention incorporating clinically guided C-reactive protein (CRP) point-of-care testing and a parental information booklet to reduce inappropriate antibiotic prescriptions for acutely ill children in Belgian primary care.

Objectives: To explore GP and parent views and experiences regarding the ARON trial intervention.

Methods: We conducted a qualitative embedded process evaluation in Belgian general practice. Semi-structured interviews were held with purposively sampled GPs and a convenience sample of mothers of acutely ill children presenting to primary care. Data were analysed using inductive thematic analysis.

Results: Thirty-four interviews were conducted with 17 GPs and 17 parents from the intervention arm, and four themes were identified. The first theme centres on the supportive role of CRP point-of-care testing in reducing diagnostic uncertainty and decreasing inappropriate prescriptions. The second theme explores the use of CRP in managing perceived parental expectations of antibiotics. The third theme discusses the use of intermediate CRP levels (above the trial's 5 mg/L cut-off) as an indicator of serious infection, as opposed to its intended role in the trial as a rule-out factor. The final theme delves into the dual functionality of the booklet, enhancing self-management and offering reassurance through safety-netting advice. A logic model depicts the assumptions and (un)anticipated dynamics underlying the relationships between these themes and their subthemes.

Conclusion: Both GPs and parents consider the intervention to be a helpful complementary tool during consultations for acutely ill children.

背景:ARON研究是一项随机对照试验,评估了一种行为干预,包括临床指导的c反应蛋白(CRP)即时检测和家长信息手册,以减少比利时初级保健中急性患儿不适当的抗生素处方。目的:探讨全科医生和家长对ARON试验干预的看法和经验。方法:我们在比利时全科实践中进行了定性嵌入式过程评价。半结构化访谈进行了有目的的抽样全科医生和一个方便的样本急性病儿童的母亲到初级保健。数据分析采用归纳专题分析。结果:对干预组的17名全科医生和17名家长进行了34次访谈,确定了四个主题。第一个主题集中在CRP即时检测在减少诊断不确定性和减少不当处方方面的支持作用。第二个主题探讨使用CRP管理感知父母对抗生素的期望。第三个主题讨论了使用中间CRP水平(高于试验的5毫克/升临界值)作为严重感染的指标,而不是其在试验中作为排除因素的预期作用。最后一个主题是探讨小册子的双重功能,即加强自我管理和通过安全网建议提供安心。逻辑模型描述了这些主题及其子主题之间关系的假设和(未预料到的)动态。结论:全科医生和家长都认为干预是一种有益的辅助工具,可用于急性患儿的咨询。
{"title":"Behavioural impact of antibiotic stewardship in children in primary care: interviews with GPs and parents.","authors":"Erinn D'hulster, Marina Digregorio, Tine De Burghgraeve, Jeroen Luyten, Samuel Coenen, Sibyl Anthierens, Jan Y Verbakel","doi":"10.1093/jacamr/dlae207","DOIUrl":"10.1093/jacamr/dlae207","url":null,"abstract":"<p><strong>Background: </strong>The ARON study, a randomized controlled trial, assesses a behavioural intervention incorporating clinically guided C-reactive protein (CRP) point-of-care testing and a parental information booklet to reduce inappropriate antibiotic prescriptions for acutely ill children in Belgian primary care.</p><p><strong>Objectives: </strong>To explore GP and parent views and experiences regarding the ARON trial intervention.</p><p><strong>Methods: </strong>We conducted a qualitative embedded process evaluation in Belgian general practice. Semi-structured interviews were held with purposively sampled GPs and a convenience sample of mothers of acutely ill children presenting to primary care. Data were analysed using inductive thematic analysis.</p><p><strong>Results: </strong>Thirty-four interviews were conducted with 17 GPs and 17 parents from the intervention arm, and four themes were identified. The first theme centres on the supportive role of CRP point-of-care testing in reducing diagnostic uncertainty and decreasing inappropriate prescriptions. The second theme explores the use of CRP in managing perceived parental expectations of antibiotics. The third theme discusses the use of intermediate CRP levels (above the trial's 5 mg/L cut-off) as an indicator of serious infection, as opposed to its intended role in the trial as a rule-out factor. The final theme delves into the dual functionality of the booklet, enhancing self-management and offering reassurance through safety-netting advice. A logic model depicts the assumptions and (un)anticipated dynamics underlying the relationships between these themes and their subthemes.</p><p><strong>Conclusion: </strong>Both GPs and parents consider the intervention to be a helpful complementary tool during consultations for acutely ill children.</p>","PeriodicalId":14594,"journal":{"name":"JAC-Antimicrobial Resistance","volume":"6 6","pages":"dlae207"},"PeriodicalIF":3.7,"publicationDate":"2024-12-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11649757/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142846479","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
JAC-Antimicrobial Resistance
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1